Introduction

- Treatment with anti-TNFα agents for paediatric patients with moderate to severe inflammatory bowel disease (IBD) has received increasing regulatory approvals since 2006. Treatment with Adalimumab and Infliximab was made available at Milton Keynes University Hospital, a secondary care setting in the Thames Valley (TV) region, following design of a shared care protocol in 2016. The service is resourced by local PeGHAN Consultant, Community Nursing team, Day Care unit and Pharmacy provisions supported by tertiary clinicians.
- The tertiary centre in Oxford remains the main provider for this specialised treatment in the Thames Valley region with only two other secondary care hospitals in the catchment area offering a similar service.
- We set out to establish both the efficacy of the service and levels of patient satisfaction by conducting a survey of our current cohort of 12 IBD patients living in Milton Keynes and receiving treatment with biologics.

Methodology

- At the time of the evaluation (Nov 2020) 12 children living within the Milton Keynes catchment area diagnosed with IBD fulfilled the inclusion criteria and received treatment with biologics.
- Clinical patient data relevant to the survey was derived from electronic patient records.
- After verbal consent was sought we conducted a telephone patient/parent interview from a standard questionnaire in our cohort receiving treatment with biologics. All families participated in the survey.
- 9 children were using our service; 3 children on second line biologics (Ustekinumab/Vedolizumab) received their care at the tertiary hospital.

Provision of Biologics in a Secondary Care Setting 5 Years On: How are We Doing?
A Service Evaluation of Current Cohort with Patient Feedback

Angela Radford¹, Joyce Youssef², Shveta Chana²

1,²Paediatric Department, Milton Keynes University Hospital (MKUH), Milton Keynes, UK

- Safe: no serious adverse reactions
- Local Service valued by 100% of users
- Holistic care and all children clinically well
- All Families feel well informed on treatment